From: Added value of 18F-FDG PET-CT in staging of Ewing sarcoma in children and young adults
Patient number | Stage of disease | Imaging modalities for comparison | SUVmax primary tumour | Discrepancy between conventional imaging and 18F-FDG PET-CT | Further imaging, biopsy, clinical follow-up | Added information from 18F-FDG PET-CT |
---|---|---|---|---|---|---|
1 | localized | US/XR/CT/MRI /BS | 3.0 | no | – | no |
2 | localized | US /XR /CT /MRI /BS | 2.2 | no | – | no |
3 | metastatic | US /XR /CT | 8.1 | FDG positive lesion | CT confirm metastases | yes (true positive lesion) |
4 | localized | US /XR /CT /MRI /BS | 20.8 | no | – | no |
5 | localized | US /XR /CT /MRI /BS | 7.2 | FDG positive lesions | biopsy –benign histology | no (false positive lesions) |
6 | metastatic | US /XR /CT /MRI | 17.0 | no | – | no |
7 | localized | US /XR /CT /MRI /BS | 3.8 | FDG positive lesion | MRI and biopsy –benign histology | no (false positive lesion) |
8 | localized | US /XR /CT /MRI /BS | 3.5 | no | – | no |
9 | localized | US /XR /CT/ MRI | 6.0 | FDG positive lesion | clinical follow up –no development of metastases | no (false positive lesion) |
10 | localized | US /XR /CT /MRI /BS | 7.0 | no | – | no |
11 | metastatic | XR /CT /MRI /BS | 4.0 | no | – | no |
12 | metastatic | XR /CT /WB-MRI /BS | – | skeletal metastases on WB MRI, none on PET-CT or bone scan | – | no (false negative study) |
13 | metastatic | XR /CT /MRI /BS | 4.4 | FDG positive lesion | MRI confirm metastases | yes (true positive lesion) |
14 | localized | CT /MRI /BS | 11.5 | no | – | no |
15 | metastatic | US /XR /CT /MRI /BS | – | FDG positive lesion | clinical follow up - rapid progression of disease | yes (true positive lesion) |
16 | metastatic | XR /CT /MRI | – | FDG positive lesion | MRI confirm metastases | yes (true positive lesion) |
17 | metastatic | XR /CT /MRI / BS | 4.3 | no | – | no |
18 | localized | XR /CT / MRI /BS | 12.6 | no | – | no |
19 | localized | XR /CT /MRI /BS | – | no | – | no |